163 related articles for article (PubMed ID: 38451188)
1. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
[TBL] [Abstract][Full Text] [Related]
2. Biallelic variants in HPDL, encoding 4-hydroxyphenylpyruvate dioxygenase-like protein, lead to an infantile neurodegenerative condition.
Ghosh SG; Lee S; Fabunan R; Chai G; Zaki MS; Abdel-Salam G; Sultan T; Ben-Omran T; Alvi JR; McEvoy-Venneri J; Stanley V; Patel A; Ross D; Ding J; Jain M; Pan D; Lübbert P; Kammerer B; Wiedemann N; Verhoeven-Duif NM; Jans JJ; Murphy D; Toosi MB; Ashrafzadeh F; Imannezhad S; Karimiani EG; Ibrahim K; Waters ER; Maroofian R; Gleeson JG
Genet Med; 2021 Mar; 23(3):524-533. PubMed ID: 33188300
[TBL] [Abstract][Full Text] [Related]
3. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
4. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
5. 4-Hydroxyphenylpyruvate Dioxygenase-Like Protein Promotes Pancreatic Cancer Cell Progression and Is Associated With Glutamine-Mediated Redox Balance.
Ye X; Wei X; Liao J; Chen P; Li X; Chen Y; Yang Y; Zhao Q; Sun H; Pan L; Chen G; He X; Lyu J; Fang H
Front Oncol; 2020; 10():617190. PubMed ID: 33537239
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of E2F6 in cancer prognosis and responses of immunotherapy.
Gong C; Tu Z; Long X; Liu X; Liu F; Liu J; Zhu X; Li J; Huang K
Int Immunopharmacol; 2024 Jan; 127():111302. PubMed ID: 38071912
[TBL] [Abstract][Full Text] [Related]
7. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
[TBL] [Abstract][Full Text] [Related]
8. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
9. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
11. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of Krüppel-like factor 3 and its carcinogenesis in pancreatic cancer.
Zhu J; Teng H; Zhu X; Yuan J; Zhang Q; Zou Y
Front Immunol; 2023; 14():1167018. PubMed ID: 37600783
[TBL] [Abstract][Full Text] [Related]
15. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
17. GLIPR2: a potential biomarker and therapeutic target unveiled - Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma.
Lin W; Zhang S; Gu C; Zhu H; Liu Y
Front Immunol; 2024; 15():1280525. PubMed ID: 38476239
[TBL] [Abstract][Full Text] [Related]
18. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
20. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
